Program Status
RecruitingPhase
Phase 3Prior Immunotherapy Allowed
YesCRC-directed Trial
YesTags
MSI-H/ MMRd, MSS/ MMRpComments
European multicenter trial comparing surgical resection and thermal ablation (radiofrequency ablation (RFA) or microwave ablation (MWA)) ) for the treatment of small-size (≤3cm) resectable colorectal liver metastases.
Location | Location Status |
---|---|
Netherlands | |
Amsterdam University Medical Center - location VUmc Amsterdam, NH 1081 |
Recruiting |
Contacts
Inclusion Criteria
Most important inclusion criteria:
At least one CRLM size ≤ 3 cm eligible for both surgical resection and thermal ablation (target lesions);
Additional unresectable CRLM should be ≤ 3 cm and ablatable (unresectable lesions);
Additional unablatable CRLM should be resectable (unablatable lesions);
Maximum number of CRLM 10;
Resectability and ablatability should be re-confirmed intra-operatively by US plus full exploration for hepatic, peritoneal and regional lymph node metastases;
ASA 1-3.
Exclusion Criteria
Most important exclusion criteria:
No target lesions suitable for both resection and ablation;
Radical treatment unfeasible or unsafe (e.g. insufficient FLR);
The presence of extrahepatic nodal or non-nodal metastases;
Immunotherapy or chemotherapy ≤ 6 weeks prior to the procedure;
Any surgical resection or focal ablative liver therapy for CRLM prior to inclusion